Want to see SG:569 full AI Analyst Report?
569 Stock Chart & Stats
S$0.08
S$0.00(0.00%)
At close: 4:00 PM EDT
S$0.08
S$0.00(0.00%)
Day’s Range― - ―
52-Week RangeS$0.07 - S$0.10
Previous CloseN/A
Volume4.90K
Average Volume (3M)97.25K
Market Cap
S$39.35M
Enterprise ValueS$78.28M
Total Cash (Recent Filing)S$6.51M
Total Debt (Recent Filing)S$43.91M
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Sep 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding511,537,700
10 Day Avg. Volume66,350
30 Day Avg. Volume97,253
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)0.65
Price to Sales (P/S)0.39
P/FCF Ratio-7.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue ReboundA strong 2025 revenue rebound (+44.7% YoY) indicates recovered demand and execution after 2024 weakness. Durable top-line growth helps absorption of fixed costs, funds continued investment in sales and R&D, and materially increases the odds of restoring sustained profitability if cost discipline holds.
Healthy Gross MarginsConsistently high gross margins (~51–55%) point to product differentiation or pricing power in the medical devices portfolio. A robust margin base provides a structural buffer against input cost inflation, allows reinvestment in innovation and commercialization, and improves chance that revenue growth converts to operating profit over time.
Equity CushionSizable shareholders' equity (~S$71–79m) gives the company balance-sheet resilience, reducing short-term solvency risk and enabling absorption of interim losses without immediate insolvency pressure. This capital base supports strategic initiatives and provides a runway while management addresses profitability and cash generation.
Bears Say
Shift To Net LossesThe shift to net losses in 2024–2025 (net margin roughly -1% to -2%) erodes retained earnings and reduces internal funding capacity. Persistent unprofitability limits resources for R&D and commercial growth, raises dependence on external capital, and weakens capacity to deliver sustainable shareholder returns absent a credible path back to positive margins.
Weak Cash GenerationOperating cash flow collapsed to about S$0.4m in 2025 and free cash flow was negative in 2024–2025, showing poor cash conversion. Weak cash generation constrains capital expenditures, working-capital flexibility, and reinvestment capacity, increasing reliance on external funding and elevating liquidity and execution risk over the medium term.
Rising LeverageDebt-to-equity increasing to ~0.58 in 2025 from ~0.22–0.44 previously signals rising financial leverage. With recent losses and weak cash flow, higher leverage raises interest and refinancing burden, reduces strategic flexibility, and heightens covenant and solvency risk if operating performance does not improve sustainably.
VicPlas International Ltd. News
569 FAQ
What was VicPlas International Ltd.’s price range in the past 12 months?
VicPlas International Ltd. lowest share price was S$0.07 and its highest was S$0.10 in the past 12 months.
What is VicPlas International Ltd.’s market cap?
VicPlas International Ltd.’s market cap is S$39.35M.
When is VicPlas International Ltd.’s upcoming earnings report date?
VicPlas International Ltd.’s upcoming earnings report date is Sep 25, 2026 which is in 51 days.
How were VicPlas International Ltd.’s earnings last quarter?
VicPlas International Ltd. released its earnings results on Mar 13, 2026. The company reported -S$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -S$0.007.
Is VicPlas International Ltd. overvalued?
According to Wall Street analysts VicPlas International Ltd.’s price is currently Overvalued.
Does VicPlas International Ltd. pay dividends?
VicPlas International Ltd. pays a Annually dividend of S$0.004 which represents an annual dividend yield of N/A. See more information on VicPlas International Ltd. dividends here
What is VicPlas International Ltd.’s EPS estimate?
VicPlas International Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does VicPlas International Ltd. have?
VicPlas International Ltd. has 511,537,700 shares outstanding.
What happened to VicPlas International Ltd.’s price movement after its last earnings report?
VicPlas International Ltd. reported an EPS of -S$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.124%.
Which hedge fund is a major shareholder of VicPlas International Ltd.?
Currently, no hedge funds are holding shares in SG:569
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
VicPlas International Ltd.
Vicplas International Ltd, established in Singapore in 1993, operates as an investment holding company with key business segments in medical devices and piping systems. The company's geographical reach includes Singapore, Malaysia, the People's Republic of China, and the United Kingdom. Its piping division focuses on the manufacturing, trading, and distribution of a variety of piping solutions. These systems are utilized for diverse applications such as waste and potable water management in residential, educational, commercial, and industrial settings; conduits for underground electrical and internal building wiring; and data and signal lines for telecommunication providers. Additionally, Vicplas is engaged in the design, development, production, and assembly of both sterile and non-sterile medical devices. The company also offers specialized project design and engineering services. Vicplas International Ltd is a subsidiary of Venner Capital S.A.
Technical Analysis
Asiamedic Limited
―
Medtecs International Corporation Ltd.
―
AJJ Medtech Holdings Limited
―
Alliance Healthcare Group Ltd.
―
Medinex Ltd.
―